← All trials
NCT00301886
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- May 1, 2006
- Completion date
- May 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Southwest Oncology GroupLead sponsor
- Loyola UniversityStudy chair
- Herbert Irving Comprehensive Cancer CenterStudy chair
- National Cancer Institute (NCI)Collaborator
- University of WashingtonStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.